Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Respiratory Sounds 1Lymphoma, Follicular 1Hematologic Neoplasms 1Bronchiolitis Obliterans Syndrome 1Asthma 1

Interventions

tofacitinib 7ibrutinib 4Rituximab 4Imatinib Mesylate 3ruxolitinib 2ofatumumab 2obinutuzumab 2nilotinib 2bosutinib 2sodium luminolate 1posaconazole 1pegfilgrastim 1montelukast 1ixekizumab 1fludarabine 1canakinumab 1belumosudil 1baricitinib 1axatilimab 1Voriconazole 1Tomography, X-Ray Computed 1Sofosbuvir 1Sirolimus 1Ribavirin 1Respiratory Function Tests 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bronchiolitis Obliterans Syndrome × Beclomethasone × Clear all
NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡